Market Snapshot
S&P Futures
3,814.5
Dow Futures
30,961
Nasdaq Futures
11,557.75
Ikena Oncology, Inc. (IKNA) stock declined over -5.19% intraday to trade at $4.20 a share on NASDAQ. The stock opened with a loss of -4.11% at $4.51 and touched an intraday high of $4.52, falling -5.19% against the last close of $4.43. The stock went to a low of $4.11 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-01 | $4.51 | $4.52 | $4.11 | $4.2 | 63,100 |
2022-06-30 | $4.38 | $4.47 | $4.15 | $4.43 | 70,100 |
2022-06-29 | $4.64 | $4.7 | $4.339 | $4.48 | 133,100 |
2022-06-28 | $4.81 | $4.97 | $4.62 | $4.7 | 118,400 |
2022-06-27 | $5.2 | $6.5 | $4.84 | $4.89 | 1,146,800 |
2022-06-24 | $4.11 | $5.37 | $4 | $5.37 | 3,455,600 |
2022-06-23 | $3.57 | $4.15 | $3.37 | $4.15 | 330,600 |
2022-06-22 | $3.36 | $3.8 | $3.22 | $3.66 | 2,595,700 |
2022-06-21 | $3.63 | $3.93 | $3.41 | $3.47 | 206,300 |
2022-06-17 | $3.48 | $3.64 | $3.41 | $3.61 | 118,500 |
Employees-
Beta-
Sales or Revenue30.98 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc. (NASDAQ: IKNA) stock price is $4.2 as of the last check on Friday, July 1. During the trading session, IKNA stock reached the peak price of $4.52 while $4.11 was the lowest point it dropped to.
The NASDAQ listed IKNA is part of Pharmaceuticals industry that operates in the broader Health Care sector. Ikena Oncology, Inc. , a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.
Mr. Francisco Oliveira
Head of Fin. & Admin. and Acting Principal Accounting Officer
Ms. Maude Tessier Ph.D.
Chief Bus. Officer
Dr. Mark Manfredi Ph.D.
Pres. CEO & Director
Dr. Sergio L. Santillana M.B.A., M.D., M.Sc., MSc
Chief Medical Officer
IKNA stock traded closed the last session at $4.2, which is $-0.23 or -5.19% lower than its previous close of $4.43. IKNA's current trading price is 48.41% lower than its 52-week high of $17.60 where as its distance from 52-week low of 2.83% is -76.14%.
Number of IKNA employees currently stands at -. IKNA operates from 645 Summer Street, Suite 101, Boston, MA 02210, United States.
Official Webiste of $IKNA is: https://ikenaoncology.com
IKNA could be contacted at IKNA operates from 645 Summer Street, Suite 101, Boston, MA 02210, United States, or at phone #857 273 8343 and can also be accessed through its website.
IKNA stock volume for the day was 63,126 shares while in the previous session number of IKNA shares traded was 63,100 . The average number of IKNA shares traded daily for last 3 months was 292.13 Thousands.
The percentage change in IKNA stock occurred in the recent session was -5.19% while the dollar amount for the price change in IKNA stock was $-0.23.
In the recent session, the day high for IKNA stock was $4.52 while the low for IKNA stock touched on the day was $4.11.
The market value of IKNA currently stands at 160.19 Million with its latest stock price at $4.2 and 36.08 Million of its shares outstanding.